n-methyl-3,4-methylenedioxyamphetamine has been researched along with Autistic Disorder in 3 studies
N-Methyl-3,4-methylenedioxyamphetamine: An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
3,4-methylenedioxymethamphetamine : A member of the class of benzodioxoles that is 1,3-benzodioxole substituted by a 2-(methylamino)propyl group at position 5.
Autistic Disorder: A disorder beginning in childhood. It is marked by the presence of markedly abnormal or impaired development in social interaction and communication and a markedly restricted repertoire of activity and interest. Manifestations of the disorder vary greatly depending on the developmental level and chronological age of the individual. (DSM-V)
| Excerpt | Relevance | Reference |
|---|---|---|
| " This infrequent dosing mitigates adverse event frequency and improves the risk/benefit ratio of MDMA, which may provide a significant advantage over medications that require daily dosing." | 2.82 | MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults. ( Danforth, AL; Grob, CS; Struble, CM; Yazar-Klosinski, B, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chaliha, D | 1 |
| Mamo, JC | 1 |
| Albrecht, M | 1 |
| Lam, V | 1 |
| Takechi, R | 1 |
| Vaccarezza, M | 1 |
| Danforth, AL | 2 |
| Grob, CS | 2 |
| Struble, C | 1 |
| Feduccia, AA | 1 |
| Walker, N | 1 |
| Jerome, L | 1 |
| Yazar-Klosinski, B | 2 |
| Emerson, A | 1 |
| Struble, CM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Placebo-controlled, Randomized, Blinded, Dose Finding Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults[NCT02008396] | Phase 2 | 12 participants (Actual) | Interventional | 2014-04-11 | Completed | ||
| Social Anxiety MDMA-Assisted Therapy Investigation (SAMATI): A Randomized, Delayed Treatment Control Phase 2 Study of the Safety and Effectiveness of Manualized MDMA-Assisted Therapy for the Treatment of Social Anxiety Disorder[NCT05138068] | Phase 2 | 90 participants (Actual) | Interventional | 2022-04-13 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The LSAS is a 24-item, semi-structured interview on the severity of Social Anxiety Disorder. The LSAS separately assesses fear and avoidance of 24 social situations. The scale is divided into 2 subscales, 13 situations concerning performance anxiety, and 11 situations pertaining to social situations. The 24 items are first rated on a Likert Scale from 0 to 3 on fear felt during the situations, and then the same items are rated regarding avoidance of the situation. Combining the total scores for the Fear and Avoidance sections provides an overall score with a maximum of 144 points and a minimum of 0 points. The higher the score, the greater the anxiety symptoms. The overall scores are interpreted as: 55-65 is moderate, 65-80 is marked, 80-95 is severe, and greater than 95 is very severe social anxiety symptoms. (NCT02008396)
Timeframe: Baseline to 1-Month Post Experimental Session 2
| Intervention | score on a scale (Mean) |
|---|---|
| Inactive Placebo With Psychotherapy | -19.3 |
| 75 mg to 125 mg MDMA With Psychotherapy | -44.1 |
The LSAS is a 24-item, semi-structured interview on the severity of Social Anxiety Disorder. The LSAS separately assesses fear and avoidance of 24 social situations. The scale is divided into 2 subscales, 13 situations concerning performance anxiety, and 11 situations pertaining to social situations. The 24 items are first rated on a Likert Scale from 0 to 3 on fear felt during the situations, and then the same items are rated regarding avoidance of the situation. Combining the total scores for the Fear and Avoidance sections provides an overall score with a maximum of 144 points and a minimum of 0 points. The higher the score, the greater the anxiety symptoms. The overall scores are interpreted as: 55-65 is moderate, 65-80 is marked, 80-95 is severe, and greater than 95 is very severe social anxiety symptoms. (NCT02008396)
Timeframe: 1-Month Post Experimental Session 2
| Intervention | score on a scale (Mean) |
|---|---|
| Inactive Placebo With Psychotherapy | 64.0 |
| 75 mg to 125 mg MDMA With Psychotherapy | 46.4 |
The LSAS is a 24-item, semi-structured interview on the severity of Social Anxiety Disorder. The LSAS separately assesses fear and avoidance of 24 social situations. The scale is divided into 2 subscales, 13 situations concerning performance anxiety, and 11 situations pertaining to social situations. The 24 items are first rated on a Likert Scale from 0 to 3 on fear felt during the situations, and then the same items are rated regarding avoidance of the situation. Combining the total scores for the Fear and Avoidance sections provides an overall score with a maximum of 144 points and a minimum of 0 points. The higher the score, the greater the anxiety symptoms. The overall scores are interpreted as: 55-65 is moderate, 65-80 is marked, 80-95 is severe, and greater than 95 is very severe social anxiety symptoms. (NCT02008396)
Timeframe: Baseline
| Intervention | score on a scale (Mean) |
|---|---|
| Inactive Placebo With Psychotherapy | 83.3 |
| 75 mg to 125 mg MDMA With Psychotherapy | 91.8 |
1 review available for n-methyl-3,4-methylenedioxyamphetamine and Autistic Disorder
| Article | Year |
|---|---|
A Systematic Review of the MDMA Model to Address Social Impairment in Autism.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Disease Models, Animal; Humans; N-Methyl-3,4-m | 2021 |
2 trials available for n-methyl-3,4-methylenedioxyamphetamine and Autistic Disorder
| Article | Year |
|---|---|
Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study.
Topics: Adult; Anxiety; Autistic Disorder; Combined Modality Therapy; Double-Blind Method; Fear; Female; Hum | 2018 |
Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study.
Topics: Adult; Anxiety; Autistic Disorder; Combined Modality Therapy; Double-Blind Method; Fear; Female; Hum | 2018 |
Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study.
Topics: Adult; Anxiety; Autistic Disorder; Combined Modality Therapy; Double-Blind Method; Fear; Female; Hum | 2018 |
Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study.
Topics: Adult; Anxiety; Autistic Disorder; Combined Modality Therapy; Double-Blind Method; Fear; Female; Hum | 2018 |
MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults.
Topics: Adult; Anxiety Disorders; Autistic Disorder; Double-Blind Method; Follow-Up Studies; Humans; N-Methy | 2016 |
MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults.
Topics: Adult; Anxiety Disorders; Autistic Disorder; Double-Blind Method; Follow-Up Studies; Humans; N-Methy | 2016 |
MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults.
Topics: Adult; Anxiety Disorders; Autistic Disorder; Double-Blind Method; Follow-Up Studies; Humans; N-Methy | 2016 |
MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults.
Topics: Adult; Anxiety Disorders; Autistic Disorder; Double-Blind Method; Follow-Up Studies; Humans; N-Methy | 2016 |